electron-transferring-flavoprotein dehydrogenase (ETF dehydrogenase)

system formed of electron-transferring flavoproteins plus EC 1.3.99.2 or EC 1.3.99.3 (butyryl-CoA dehydrogenase or acyl-CoA dehydrogenase) which reduces ubiquinone & other acceptors, defects in ETFDH are the cause of glutaric aciduria type IIc

Also Known As:

Networked: 31 relevant articles (0 outcomes, 1 trials/studies)

Bio-Agent Context: Research Results

Experts

1.	Yamaguchi, Seiji: 4 articles (08/2019 - 05/2008)
2.	Fukuda, Seiji: 3 articles (08/2019 - 05/2008)
3.	Hasegawa, Yuki: 3 articles (08/2019 - 05/2008)
4.	Kobayashi, Hironori: 3 articles (08/2019 - 05/2008)
5.	Araújo, Wagner L: 2 articles (02/2022 - 05/2010)
6.	Nunes-Nesi, Adriano: 2 articles (02/2022 - 05/2010)
7.	Angelini, Corrado: 2 articles (04/2015 - 09/2013)
8.	DiMauro, Salvatore: 2 articles (10/2011 - 08/2007)
9.	Endo, Mitsuru: 2 articles (06/2010 - 05/2008)
10.	Yotsumoto, Yuka: 2 articles (06/2010 - 05/2008)

Related Diseases

1.	Multiple Acyl Coenzyme A Dehydrogenase Deficiency 01/01/1990 - "Glutaric aciduria type II: autopsy study of a case with electron-transferring flavoprotein dehydrogenase deficiency." 11/01/2018 - "Late-onset multiple acyl-coenzyme A dehydrogenase deficiency (MADD) mainly affects the neck extensor muscle group, which has been confirmed by novel mutations in electron-transferring-flavoprotein dehydrogenase (ETFDH). " 08/15/2011 - "Multiple acyl-CoA-dehydrogenase deficiency (MADD)--a novel mutation of electron-transferring-flavoprotein dehydrogenase ETFDH." 12/01/2010 - "Novel ETF dehydrogenase mutations in a patient with mild glutaric aciduria type II and complex II-III deficiency in liver and muscle." 09/01/2002 - "Glutaric acidemia type II: gene structure and mutations of the electron transfer flavoprotein:ubiquinone oxidoreductase (ETF:QO) gene."
2.	Muscular Diseases (Myopathy) 10/01/2011 - "Most patients with myopathy were found to harbor other genetic defects (mutations in electron-transferring-flavoprotein dehydrogenase or mitochondrial DNA). " 06/01/2013 - "Our previous data showed that in a group of Chinese patients, a mild type of MADD characterized by myopathy with clinically no other systemic involvement was caused by mutations in electron transfer flavoprotein dehydrogenase (ETFDH) gene, which encodes electron transfer flavoprotein: ubiquinone oxidoreductase (ETF:QO). " 04/01/2015 - "This review is focused on recent advances about GSDII and its treatment, and the most recent notions about the management and treatment of other metabolic myopathies will be briefly reviewed, including glycogenosis type V (McArdle disease), glycogenosis type III (debrancher enzyme deficiency or Cori disease), CPT-II deficiency, and ETF-dehydrogenase deficiency (also known as riboflavin-responsive multiple acyl-CoA dehydrogenase deficiency or RR-MADD). " 09/01/2013 - "Pharmacological, immunotherapy, nutritional, and physical/rehabilitative treatments for late-onset Pompe disease and other metabolic myopathies are covered, including treatments for defects in glycogen metabolism, such as glycogenosis type V (McArdle disease), and glycogenosis type III (debrancher enzyme deficiency), and defects in lipid metabolism, such as carnitine palmitoyltransferase II deficiency and electron transferring flavoprotein dehydrogenase deficiency, or riboflavin-responsive multiple acyl-CoA dehydrogenase deficiency. "
3.	Starvation 09/01/2005 - "The critical role of Arabidopsis electron-transfer flavoprotein:ubiquinone oxidoreductase during dark-induced starvation." 02/01/2022 - "The role of the electron-transfer flavoprotein: ubiquinone oxidoreductase following carbohydrate starvation in Arabidopsis cell cultures." 05/01/2010 - "The process of dark-induced senescence in plants is relatively poorly understood, but a functional electron-transfer flavoprotein/electron-transfer flavoprotein:ubiquinone oxidoreductase (ETF/ETFQO) complex, which supports respiration during carbon starvation, has recently been identified. "
4.	Metabolic Diseases (Metabolic Disease) 12/01/2022 - "Multiple acyl-CoA dehydrogenase deficiency (MADD) is an inherited metabolic disease caused by a defect in electron transfer flavoprotein alpha (ETFA), ETF beta (ETFB), or ETF dehydrogenase (ETFDH), and riboflavin metabolism disorders have recently been reported to present as mimicking MADD. " 10/17/1997 - "Defects in electron transfer flavoprotein (ETF) or its electron acceptor, electron transfer flavoprotein-ubiquinone oxidoreductase (ETF-QO), cause the human inherited metabolic disease glutaric acidemia type II. In this disease, electron transfer from nine primary flavoprotein dehydrogenases to the main respiratory chain is impaired. "
5.	Glycogen Storage Disease Type V (McArdle's Disease) 04/01/2015 - "This review is focused on recent advances about GSDII and its treatment, and the most recent notions about the management and treatment of other metabolic myopathies will be briefly reviewed, including glycogenosis type V (McArdle disease), glycogenosis type III (debrancher enzyme deficiency or Cori disease), CPT-II deficiency, and ETF-dehydrogenase deficiency (also known as riboflavin-responsive multiple acyl-CoA dehydrogenase deficiency or RR-MADD). " 09/01/2013 - "Pharmacological, immunotherapy, nutritional, and physical/rehabilitative treatments for late-onset Pompe disease and other metabolic myopathies are covered, including treatments for defects in glycogen metabolism, such as glycogenosis type V (McArdle disease), and glycogenosis type III (debrancher enzyme deficiency), and defects in lipid metabolism, such as carnitine palmitoyltransferase II deficiency and electron transferring flavoprotein dehydrogenase deficiency, or riboflavin-responsive multiple acyl-CoA dehydrogenase deficiency. "

Related Drugs and Biologics

1.	Electron-Transferring Flavoproteins (Electron Transfer Flavoprotein)
2.	Oxidoreductases (Dehydrogenase)
3.	Riboflavin (Vitamin B2)
4.	Flavoproteins
5.	Acyl-CoA Dehydrogenases
6.	Enzymes
7.	Carnitine palmitoyl transferase 2 deficiency
8.	Complementary DNA (cDNA)
9.	Ubiquinone
10.	Trace Elements (Biometals)

Related Therapies and Procedures

1.	Immunotherapy